Adam Koppel, MD, PhD
Adam Koppel rejoined Bain Capital in 2016 as managing director of the Bain Capital Life Sciences Fund. He had initially joined Bain Capital Public Equity in 2003, where he was a leader within the healthcare sector until mid-2014. During the period mid-2014 to mid-2016, Adam was at Biogen, where he served as executive vice president of corporate development and chief strategy officer.
He sits on the board of directors of Solid Biosciences (NASDAQ: SLDB), Dicerna Pharmaceuticals (NASDAQ: DRNA), Trevena (NASDAQ: TRVN), Aptinyx Inc., and Foghorn Therapeutics. He is a former director of PTC Therapeutics (NASDAQ: PTCT).
Prior to joining Bain Capital in 2003, Adam was an associate principal at McKinsey & Company in New Jersey, where he served a variety of healthcare companies.
Adam sits on the Newton-Wellesley Hospital Board of Trustees, the Partners Healthcare Innovation Advisory Board, and the Society for Neuroscience Investment Committee.
Adam graduated magna cum laude from Harvard University with an AB and AM in history and science. He received his MD and PhD in neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from the Wharton School at the University of Pennsylvania, where he was a Palmer Scholar